Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunome, Inc. (IMNM : NSDQ)
 
 • Company Description   
Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

Number of Employees: 118

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.64 Daily Weekly Monthly
20 Day Moving Average: 1,042,407 shares
Shares Outstanding: 87.01 (millions)
Market Capitalization: $751.78 (millions)
Beta: 1.92
52 Week High: $16.81
52 Week Low: $5.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.75% -14.77%
12 Week 9.23% -7.82%
Year To Date -18.64% -21.08%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18702 N. CREEK PARKWAY SUITE 100
-
BOTHELL,WA 98011
USA
ph: 425-939-7410
fax: -
investors@immunome.com http://www.immunome.com
 
 • General Corporate Information   
Officers
Clay B. Siegall - President; Chief Executive Officer and Director
Max Rosett - Chief Financial Officer
Isaac Barchas - Director
Jean-Jacques Bienaime - Director
James Boylan - Director

Peer Information
Immunome, Inc. (CORR.)
Immunome, Inc. (RSPI)
Immunome, Inc. (CGXP)
Immunome, Inc. (BGEN)
Immunome, Inc. (GTBP)
Immunome, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45257U108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 87.01
Most Recent Split Date: (:1)
Beta: 1.92
Market Capitalization: $751.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.20 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.45
Price/Cash Flow: -
Price / Sales: 68.73
EPS Growth
vs. Year Ago Period: -52.94%
vs. Previous Quarter: 38.10%
Sales Growth
vs. Year Ago Period: 184.35%
vs. Previous Quarter: 6.87%
ROE
06/30/25 - -
03/31/25 - -71.65
12/31/24 - -62.99
ROA
06/30/25 - -
03/31/25 - -60.36
12/31/24 - -52.94
Current Ratio
06/30/25 - -
03/31/25 - 10.49
12/31/24 - 4.08
Quick Ratio
06/30/25 - -
03/31/25 - 10.49
12/31/24 - 4.08
Operating Margin
06/30/25 - -
03/31/25 - -1,567.26
12/31/24 - -1,629.52
Net Margin
06/30/25 - -
03/31/25 - -1,875.21
12/31/24 - -3,240.38
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,875.21
12/31/24 - -3,240.38
Book Value
06/30/25 - -
03/31/25 - 3.53
12/31/24 - 2.27
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©